Reviewed by MedNext Clinical Team
Rivaroxaban is a direct oral factor Xa inhibitor that has largely replaced warfarin for stroke prevention in non-valvular atrial fibrillation (AF) and for treatment and prevention of venous thromboembolism (VTE). Its once-daily dosing for AF is a practical advantage, though there are important prescribing nuances to understand [1].
Rivaroxaban vs Apixaban
Apixaban and rivaroxaban are both factor Xa inhibitors but differ in key ways. Rivaroxaban is once-daily (for AF and long-term VTE prevention), while apixaban is twice-daily. Rivaroxaban has a higher proportion of renal elimination (~33% unchanged), whereas apixaban relies less on renal clearance (~27%). Apixaban demonstrated lower rates of major bleeding in clinical trials, though direct head-to-head comparisons are limited. Clinical factors and patient preference should guide the choice between them.
The Food Requirement
A frequently overlooked but clinically important point: rivaroxaban at doses of 15 mg and 20 mg (used for AF and VTE treatment) must be taken with food to achieve adequate bioavailability. Without a meal, absorption is significantly reduced, potentially resulting in sub-therapeutic drug levels. The 10 mg dose (used for VTE prophylaxis) does not have this requirement. Patient counselling on this point is essential.
Renal Thresholds
Rivaroxaban should be used with caution as renal function declines, and is generally contraindicated when creatinine clearance (CrCl) falls below 15 mL/min. For AF, dose reduction considerations apply when CrCl falls below 50 mL/min in combination with other risk factors. Renal function should be assessed before initiating and at least annually thereafter — more frequently in patients with deteriorating renal function or intercurrent illness [1].
Managing Bleeding
Unlike warfarin, rivaroxaban does not have a routine monitoring parameter. In the event of major bleeding, andexanet alfa is a specific reversal agent approved for factor Xa inhibitors. Four-factor prothrombin complex concentrate (4F-PCC) is an alternative reversal option where andexanet alfa is unavailable. Tranexamic acid can be used as an adjunct for localised bleeding. The relatively short half-life of rivaroxaban (5–9 hours in healthy individuals) means that delayed last dose timing should always be considered in the assessment of bleeding risk.
References
- Patel MR, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. NEJM. 2011;365:883-891.